Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2018

Open Access 01-12-2018 | Case report

Streptococcus agalactiae meningoencephalitis associated with gastroesophageal reflux disease and chronic proton pump inhibitors use, in a 9 month-old infant: a case report

Authors: Victoria Bîrluţiu, Codruța Mihaela Luca, Rareș-Mircea Bîrluțiu

Published in: BMC Pediatrics | Issue 1/2018

Login to get access

Abstract

Background

Streptococcus agalactiae (Group B Streptococcus) is recognized as the etiologic agent of newborn and infant meningitis, aged up to 90 days, starting from the colonization of the maternal genital or gastrointestinal tract, but it is rarely responsible for meningitis in old infants.

Case presentation

We present the case of a 9 month-old infant diagnosed with S. agalactiae meningoencephalitis associated with chronic gastroesophageal reflux disease treated with a proton pump inhibitor (PPI).

Conclusion

The use of a PPI is a risk factor for ultra-late onset of Group B Streptococcus meningitis. The use of PPI in infants should be closely monitored in the light of changes in the gut microbiota, in the oropharyngeal and of the respiratory tract colonization, potentially with pathogenic flora.
Appendix
Available only for authorised users
Literature
1.
Maisey HC, Doran KS, Nizet V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev Mol Med. 2008;10:e27.CrossRefPubMedPubMedCentral
2.
Slotved HC, Kong F, Lambertsen L, Sauer S, Gillbert GL. Serotype IX, a proposed new Streptococcus agalactiae serotype. J Clin Microbiol. 2007;45:2929–36.CrossRefPubMedPubMedCentral
3.
Nizet V, Kim KS, Stins M, Jonas M, Chi EY, Nguyen D, et al. Invasion of brain microvascular endothelial cells by group B streptococci. Infect Immun. 1997;65(12):5074–81.PubMedPubMedCentral
4.
Alkuwaity K, Taylor A, Heckels JE, Doran KS, Christodoulides M. Group B streptococcus interactions with human meningeal cells and astrocytes in vitro. PLoS One. 2012;7(8):e42660.CrossRefPubMedPubMedCentral
5.
Levent F, Baker CJ, Rench MA, Edwards MS. Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J. 2010;29(11):1009–12.PubMed
6.
Guilbert J, Levy C, Cohen R, Renolleau S, Delacourt C. Groupe des Pédiatres et Microbiologistes de l’Observatoire National des Méningites Bactériennes de l’Enfant. Streptococcus B meningitis in infants older than 3 months. Arch Pediatr. 2008;15(Suppl 3):S133–7.CrossRefPubMed
7.
Georget-Bouquinet E, Bingen E, Aujard Y, Levy C, Cohen R. Groupe des Pédiatres et Microbiologistes de l’Observatoire National des Méningites Bactériennes de l’Enfant (Group B streptococcal meningitis’clinical, biological and evolutive features in children). Arch Pediatr. 2008;15(Suppl 3):S126–32.CrossRefPubMed
8.
Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, et al. Active bacterial core surveillance/emerging infections program network. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299(17):2056–65.CrossRefPubMed
9.
Managoli S, Chaturvedi P, Vilhekar KY. Group B streptococcal meningitis in a 5-year-old boy. Indian J Pediatr. 2003;70(6):509–11.CrossRefPubMed
10.
Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28(6):615–20.CrossRefPubMed
11.
Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56.CrossRefPubMed
12.
Pérez-Cobas AE, Artacho A, Ott SJ, Moya A, Gosalbes MJ, Latorre A. Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Front Microbiol. 2014;5:335.PubMedPubMedCentral
13.
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–60.CrossRefPubMed
14.
Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950–5.CrossRefPubMed
15.
Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22:761–6.CrossRefPubMedPubMedCentral
16.
Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–50.CrossRefPubMed
17.
de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk_lafaber AB, Siersema PD, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther. 2012;36:941–9.CrossRefPubMed
18.
19.
Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53.CrossRefPubMed
20.
Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–42.CrossRefPubMed
21.
Howden C. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30(1):29–33.CrossRefPubMed
22.
Yu EW, Blackwell T, Ensrud KE, Hiller TA, Lane NE, Orwoll E, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251–9.CrossRefPubMedPubMedCentral
23.
de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989–98.CrossRefPubMed
Metadata
Title
Streptococcus agalactiae meningoencephalitis associated with gastroesophageal reflux disease and chronic proton pump inhibitors use, in a 9 month-old infant: a case report
Authors
Victoria Bîrluţiu
Codruța Mihaela Luca
Rareș-Mircea Bîrluțiu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2018
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-018-0995-0

Other articles of this Issue 1/2018

BMC Pediatrics 1/2018 Go to the issue

Case report

A case of incomplete Kawasaki disease with extremely high serum ferritin and interleukin-18 levels

Research article

Hospitalisation after birth of infants: cross sectional analysis of potentially avoidable admissions across England using hospital episode statistics

Research article

Elevated central venous pressure is associated with increased mortality in pediatric septic shock patients

Study protocol

Discovering the sense of touch: protocol for a randomised controlled trial examining the efficacy of a somatosensory discrimination intervention for children with hemiplegic cerebral palsy

Research article

Prevalence and seasonality of common viral respiratory pathogens, including Cytomegalovirus in children, between 0–5 years of age in KwaZulu-Natal, an HIV endemic province in South Africa

Case report

Clinical and molecular report of c.1331 + 1G > A mutation of the AAAS gene in a Moroccan family with Allgrove syndrome: a case report